Constantino Michael T. - 18 May 2026 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Reporting relationship: Director
Issuer ticker: HUMA
Reported as of: 18 May 2026
Net transaction value: +$9,840
SEC form: 4
Accepted by SEC: 20 May 2026, 16:32:09 UTC
Prior SEC filing: 16 Jun 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael T. Constantino by Dale A. Sander as Attorney-in-Fact

Key filing fact

Constantino Michael T. filed Form 4 for Humacyte, Inc. (HUMA) on 20 May 2026.

Key facts

This page summarizes Constantino Michael T.'s Form 4 filing for Humacyte, Inc. (HUMA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 May 2026, 16:32.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: +$9,840.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001817285 Primary reporting owner

Constantino Michael T.

Relationship: Director
Address: 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Signature: /s/ Michael T. Constantino by Dale A. Sander as Attorney-in-Fact
Signature date: 20 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HUMA transaction

Common Stock

Purchase

Transaction value: $9,840
Shares: +11,000
Change %: +33%
Price: $0.8945
Shares after: 43,950
Date: 18 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.8922 to $0.8958. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.